Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 101 | ETA2024 | Next issue

46th Annual Meeting of the European Thyroid Association (ETA) 2024

Poster Presentations

Thyroid cancer treatment

ea0101ps1-06-01 | Thyroid cancer treatment | ETA2024

Intraoperative neuromonitoring does not decrease the risk of vocal cord palsy associated with thyroid cancer surgeries, but cumulative experience over time may

Hwang Ki-Tae Hwang Ki-Tae

Background: The effectiveness of intraoperative neuromonitoring (IONM) in reducing the risk of vocal cord palsy (VCP) after thyroidectomy is controversial. This study aimed to evaluate the impact of IONM on VCP rates, identify risk factors, and assess the trend of VCP rates over time.Methods: This retrospective observational study included consecutive patients who underwent thyroidectomy for thyroid cancer between March 2014 and June 2022. VCP rates were...

ea0101ps1-06-02 | Thyroid cancer treatment | ETA2024

Impact of short lenvatinib interruptions in advanced thyroid cancer patients

Trevisan Matteo , de Leo Simone , Colombo Carla , Lugaresi Marina , Ceruti Daniele , Moneta Claudia , Succi Massimiliano , Fugazzola Laura

Objectives: Lenvatinib treatment significantly improves the outcome in advanced, radioiodine refractory, differentiated thyroid cancer (DTC) patients. The treatment efficacy relies on maintaining the drug dose intensity, which can be complex due to lenvatinib toxicities. Data from the SELECT study showed that interruptions for over 10% of the treatment period detrimentally affects prognosis. Nevertheless, the increasing knowledge from real-life experiences resulted in improved...

ea0101ps1-06-03 | Thyroid cancer treatment | ETA2024

Risk factors predicting papillary thyroid cancer recurrence: a single-surgeon experience

Seon Kim Yon

Background: The incidence of thyroid cancer is increasing worldwide. In Korea, the incidence of thyroid cancer increased from 1999 to 2011, but subsequently decreased from 2012 until recently. The most common type of thyroid cancer is papillary thyroid cancer (PTC). Although PTC has an excellent prognosis, a recurrence rate of 30% has been reported.Methods: This study retrospectively reviewed 2,842 patients who underwent primary thyroidectomy for PTC by ...

ea0101ps1-06-04 | Thyroid cancer treatment | ETA2024

Radiofrequency ablation (RFA) for structural incomplete response (SIR) to therapy in differentiated thyroid cancer (DTC)

Gkeli Myrsini , Kapama Katerina , Gkousis Pyrros , Koursaros Panayiotis , Kokkinis Christos , Zozolou Maria , Simeakis George

Objective: SIR may occur in, 2 - 6% of ATA low risk and 67 - 75% of high risk DTC. Regarding locoregional disease, surgery is the optimal therapeutic modality if, the smallest dimension (sd) of the targeted node is ≥ 8 or 10 mm (central or lateral compartment). In the presence of, smaller nodes, contraindications or, patient’s unwillingness for reoperation, active surveillance or minimally invasive treatments (MIT), may be considered. The purpose of this study is to...

ea0101ps1-06-05 | Thyroid cancer treatment | ETA2024

Counselling of thyroid cancer patients, what patient need to know from surgeon about treatment options, complications & follow-up

Hasan Dewan

Background: Patients with thyroid swelling, specially advanced thyroid carcinoma shows a poor prognosis, and poses challenges during surgery & with risk of more post-operative complications. For this subset of patients. Important goal is preserving quality of life.Methods: Different private hospitals & clinics and surgeons involved in thyroid surgery were involved in this survey in revealing the level of knowledge and the application of communica...

ea0101ps1-06-06 | Thyroid cancer treatment | ETA2024

Molecular profile can influence the PFS in radioiodine-refractory thyroid cancer patients treated with lenvatinib

Minaldi Elisa , Ramone Teresa , Ciampi Raffaele , Romei Cristina , Torregrossa Liborio , Gambale Carla , Matrone Antonio , Elisei Rossella

Objectives: Limited and conflicting data exist regarding mutational profiles and clinical responses to tyrosine-kinase inhibitors (TKI) in advanced radioiodine refractory thyroid cancer (RAIR-TC). The role of BRAF/RAS mutational status on progression-free survival (PFS) in patients treated with lenvatinib is controversial. This study aims to assess the impact of genetic profiles on clinical responses to lenvatinib in RAIR-TC.Materials and methods: We ana...

ea0101ps1-06-07 | Thyroid cancer treatment | ETA2024

The role of primary non-selective laryngeal reinnervation in the treatment of invasive thyroid cancer

Tovkai Oleksandr , Palamarchuk Volodymyr , Yuzvenko Tetiana , Solomennikova Nataliia , Voitenko Volodymyr , Tovkai Andrii , Yuzvenko Violetta

Introduction: Cases of locally advanced thyroid cancer can lead to spontaneous or irreversible intraoperative damage of RLN. For the correction of dysphonia with OCPS, are used static methods and the physiological reinnervation of the larynx.Methods: A prospective monocenter study of the results of 61 cases of primary larynx reinnervation in the treatment of patients with invasive forms of differentiated thyroid cancer and initial laryngeal abduction par...

ea0101ps1-06-08 | Thyroid cancer treatment | ETA2024

Can nocturnal administration of lenvatinib based on time pharmacology reduce adverse events?

Suzuki Akifumi , Sugino Kiminori , Ohara Ryoji , Kuga Yoko , Matsui Ai , Yoshioka Kana , Saito Yoshiyuki , Masaki Chie , Akaishi Junko , Hames Kiyomi , Okamura Ritsuko , Tomoda Chisato , Matsuzu Kenichi , KItagawa Wataru , Nagahama Mitsuji , Ito Koichi

Purpose: Molecularly targeted drugs are indispensable therapeutic tools for the treatment of unresectable differentiated thyroid cancer. Lenvatinib (LEN) is listed as a preferred regimen in the NCCN guidelines, and is a highly effective anti-tumor agent, but is also associated with a high rate of adverse events (AEs), which may be related to prognosis. AE management is key to LEN therapy. Although there is no recommendation in the package insert regarding the recommended time ...

ea0101ps1-06-09 | Thyroid cancer treatment | ETA2024

Surgical management of medullary thyroid carcinoma with tracheal invasion

mohamed Trabelsi Wejdan , Methnani Alia , Zitoun Oumaima , Baraham Rim , Dhaha Mohamed , Jbali Souheil , Dhambri Sawsen , Kedous Skander

Introduction: Tracheal infiltration by thyroid carcinoma causes tracheal stenoses and hemoptysis, which is often fatal. Therefore, surgical treatment of thyroid carcinoma should be performed early to ensure patency of the airway.Aim: This report deals with the diagnosis and surgical treatment of a patient undergoing resection of the trachea for recurrent thyroid medullary carcinoma infiltrating the trachea in Salah Azeize institute in March 2021.<p c...

ea0101ps1-06-10 | Thyroid cancer treatment | ETA2024

The risk of hypocalcemia in total thyroidectomy with comprehensive mediastinal-recurrent cellular and lymph-node dissection

Zitoun Oumaima , Brahem Rim , Makhlouf Youssef , Methneni Alia , Dhaha Mohamed , Jbali Souhail , Dhambri Sawsen , Kdous Skander

Objectives: We aim to correlate the risk of hypocalcemia with mediastinal-recurrent cellular and lymph-node dissection, whether unilateral or bilateral, and incidental parathyroidectomy after total thyroidectomy.Material and Methods: A retrospective study was conducted over a four-year period from 2020 to 2023 in the Department of Otorhinolaryngology and Cervicofacial Surgery at Salah Azaiz Institute in Tunisia. The study included 85 patients who underwe...